First English Translation Revives the 1996 Paper That Named Cardio-Oncology

Thirty years after a young Italian cardiologist coined the term that would define an entire subspecialty, the journal Cardio-Oncology has published a commentary and the first English-language translation of the 1996 monograph that introduced the words “cardio-oncology” and “cardio-oncologist” to the medical literature. The original paper, written by Dr. Daniela Cardinale during her first year as a cardiologist at the Istituto Europeo di Oncologia in Milan, appeared in Cardiologia, the official journal of the Italian Society of Cardiology, under the title “A New Frontier: Cardio-oncology.” Until now, the manuscript existed only as a citation in PubMed with no accessible abstract or full text in English or Italian, meaning that awareness of the inaugural use of the term and the outline of the field’s scope was largely confined to readers able to access and comprehend the original Italian version.

The newly published commentary, authored by Charles B. Porter and Daniela M. Cardinale to mark the 30th anniversary, presents what the authors believe is the first English rendering of the 1996 publication. Beyond its historical interest, the translation reveals how remarkably prescient the original monograph was. In it, Cardinale enumerated seven components of the then-unnamed discipline: operative risk, cardiotoxicity, monitoring of cardiac function, the role of echocardiography, treatment, secondary cardiac tumors, and a look into the future. The commentary argues that these seven components established a foundation for the expansion of cardio-oncology in the first quarter of the twenty-first century and for the development of one of cardiology’s most collaborative subspecialties.

The 1996 text opens with a striking diagnosis of how the relationship between the two specialties had changed. Until a few years earlier, the cardiologist approached the assessment of the oncology patient, in Cardinale’s words, with extreme and almost resigned prudence, and perhaps little interest, first weighing whether it was appropriate to propose diagnostic tests, especially invasive ones, or to begin demanding long-term cardiac therapies in patients with limited life expectancy. Things had changed: tumors were more often diagnosed at an early stage, new and more effective chemotherapeutic drugs had become available, and surgical techniques had been refined and extended to older patients and those with more advanced disease. A steadily expanding population of cancer patients had emerged whose life expectancy was very different from the past, and the cardiologist’s role had to adapt accordingly.

Cardinale was careful to specify that cardio-oncology was not the simple union of two disciplines but a truly autonomous branch, setting itself the ambitious task of widening therapeutic options for cancer patients, making an ever-increasing number of them eligible for more aggressive pharmacologic and surgical treatments while controlling the complications and side effects of those antineoplastic treatments. Her first component, operative risk, addressed one of the most frequent questions the surgical oncologist put to the cardiologist. Because surgery to eradicate the primary tumor had fundamental implications for prognosis, the question was no longer whether an intervention was feasible but how far its limits could be pushed. She called for a re-evaluation of classical surgical cardiac risk through a new score system specific to anesthesiology and oncologic surgery, and described the cardio-oncologist’s task of preparing the highest-risk patients, optimizing and intensifying therapy so they could face complex and prolonged procedures under continuous perioperative cardiovascular monitoring.

The section on cardiotoxicity remains central to the field today. Cardinale distinguished two types: early or acute cardiotoxicity, which is not dose-dependent and can occur during, immediately after, or a few days after the first administration of a chemotherapeutic drug, often manifesting with electrocardiographic abnormalities, arrhythmic phenomena, and conduction disturbances that are generally transient; and late or chronic cardiotoxicity, which is more frequent and mainly reflects a dose-dependent degenerative cardiomyopathy that may appear even very late after the last dose. She noted that combinations of chemotherapeutic agents or radiotherapy can have a synergistic effect in developing this cardiomyopathy, and that recognized risk factors include advanced age, previous heart disease, evidence of cardiac metastases, and previous radiotherapy. Critically, she observed that while no threshold dose exists below which there is no risk of cardiotoxicity, there is wide individual variability in the onset and progression of toxic cardiac damage.

Perhaps the most forward-looking passage concerns monitoring. Cardinale wrote that an ideal monitoring method was still being sought: reliable and easily repeatable, non-invasive and inexpensive, able to detect early signs of cardiotoxicity and follow their evolution over time. She reviewed the options of her era, from endomyocardial biopsy, which proved sensitive but invasive and unable to show the overall extent of damage, to electrocardiographic measures with little predictive value, to nuclear techniques using radioactive tracers such as indium-111 labeled antimyosin antibodies, iodine-123 metaiodobenzylguanidine, thallium-201, and technetium-99 sestamibi, whose changes in myocardial uptake were observed before any reduction in left ventricular ejection fraction could be detected. Echocardiography, because it is non-invasive, safe, and repeatable, appeared to her to be the ideal technique, with segmental wall-motion abnormalities during anthracycline chemotherapy preceding alterations in global function and serving as the first functional warning sign of reversible damage.

On treatment, the 1996 monograph acknowledged that no standardized, universally accepted guidelines existed on how and when to modify or stop chemotherapy in the presence of asymptomatic cardiac dysfunction, and that supportive cardiac therapy at these early stages was even less clearly defined. Cardinale argued that efforts should focus on initiating treatment much earlier, as soon as alarm markers were detected, when cardiotoxic damage was still potentially reversible. She also gave separate consideration to cardioprotection, proposing that concomitant administration of certain pharmacologic agents acting on the mechanisms responsible for cardiotoxic effects, including calcium overload and the production of oxygen free radicals, might protect the myocardium and reduce chemotherapy-induced damage, thus allowing intensification of oncologic treatment. Among the agents she listed were N-acetylcysteine, digoxin, L-carnitine, calcium-channel blockers, coenzyme Q10, superoxide dismutase, glutathione, and dexrazoxane, for which numerous trials had already shown a lower incidence of anthracycline-induced heart disease.

The commentary’s 2026 discussion draws explicit lines from these early ideas to contemporary practice. Although contemporary categorizations of cardio-oncology do not follow the 1996 components in lockstep, the authors note that the strategy of preparation, optimization, and continuous monitoring now applies to new therapies such as hematopoietic stem cell transplantation and CAR T-cell therapies. Stem cell candidates are now evaluable with cardiovascular risk profiling tools such as the evolving CARE-BMT risk calculator, which defines cardiovascular risk based on patient and treatment characteristics without defining patients whose risk profiles are too high to be acceptable transplantation candidates. Understanding of cardiovascular adverse events associated with CAR T-cell therapies is at a different phase, but both areas are advancing rapidly as cardio-oncologists’ roles evolve.

The commentary also acknowledges what has and has not changed. Despite intensive study by Cardinale and an internationally based array of experts in biomarker and imaging surveillance, whose consensus and review statements have followed since 1996, her statement about monitoring remains true today: an ideal monitoring method is still being sought. Her proposal that pharmacologic agents could allow oncological treatment to be continued or even intensified, the authors write, describes the strategy of permissive cardiotoxicity, a term not specifically enunciated until 2022, the same year the first European Society of Cardiology guideline on cardio-oncology codified approaches to risk assessment, surveillance, and management. Her own 2006 report of enalapril as a cardioprotective agent in patients receiving potentially cardiotoxic high-dose chemotherapy grew directly from the 1996 framework. In a closing reflection, Cardinale recalls the excitement of navigating a frontier without codified rules and urges young cardiologists today not to hesitate to enter fields still taking shape, describing a future discipline that will integrate clinical data, biomarkers, advanced imaging, and artificial intelligence to predict cardiotoxicity and tailor treatments for each patient.

Subject of Research: The 30th anniversary of the 1996 paper that introduced the term cardio-oncology, with its first English translation and a commentary linking its seven components to modern practice.

Article Title: Celebrating the 30th anniversary of the introduction of cardio-oncology: commentary and the first english translation of the report

Article References: Porter, C. B., & Cardinale, D. M. (2026). Celebrating the 30th anniversary of the introduction of cardio-oncology: commentary and the first english translation of the report. Cardio-Oncology, 12(1), Article 132. https://doi.org/10.1186/s40959-026-00589-6

Image Credits: AI Generated

DOI: 10.1186/s40959-026-00589-6

Keywords: cardio-oncology, cardiotoxicity, anthracyclines, echocardiography, cardioprotection, cardiac monitoring, oncology patients, medical history, ESC guideline, CAR T-cell therapy, stem cell transplantation, Daniela Cardinale